Vanda Pharmaceuticals reported $198.77M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 450.82M 375.59M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 524.42M 98.93M Sep/2026
J&J USD 25.4B 89M Sep/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.31M 98.69M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 14.44B 2.49B Sep/2026
Takeda JPY 1.19T 32.9B Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 151.75M 1.43M Sep/2026